Radiation-induced pericarditis

Article written and reviewed by Dr Luca Moretti

The radiation-induced pericarditis is a manifestation of pericardial injury associated with exposure of the heart to ionizing radiation used in cancer treatment. It may present during treatment or shortly afterward, or emerge years later with effusion, fibrous thickening, and constriction. The term therefore encompasses biologically different conditions: active inflammation that may respond to treatment and a scar lesion in which the predominant problem is loss of distensibility.

Previous thoracic irradiation does not, by itself, establish the cause of a new effusion. Neoplastic pericarditis, infections, and the effects of antineoplastic drugs remain essential alternatives, including in long-term survivors. Diagnosis requires reconstruction of the exposure, definition of the pericardial phenotype, and assessment of the other cardiac structures, because the coronary arteries, valves, and myocardium may be injured at the same time.

Clinical relevance depends on the rate of fluid accumulation, the presence of reversible inflammation, and the extent of fibrosis. The therapeutic pathway must relate these elements to the oncologic situation and procedural feasibility, without attributing every cardiopulmonary symptom arising after treatment to radiotherapy.

Exposure, latency, and factors that modify risk

Thoracic irradiation may involve the pericardium during treatment of mediastinal lymphomas and lung, esophageal, and breast cancers, particularly when part of the heart lies within the treatment field. Risk does not simply depend on the name of the tumor or the dose prescribed to the neoplasm: it is necessary to know how much radiation actually reached the heart and which regions were exposed. Extrathoracic treatments, in the absence of meaningful cardiac exposure, do not have the same causal plausibility.

Dosimetry includes mean heart dose, dose distribution, and the volume of exposed structures. A relatively low mean dose may conceal a pericardial region exposed to higher doses. Fractionation, treatment duration, any reirradiation, and overlap of fields contribute to risk. Planning constraints are preventive tools and must be interpreted in the context of the technique and cancer site; they are not diagnostic thresholds that allow disease to be excluded in an individual patient.

Latency is variable. Early inflammation may appear during the radiotherapy course or in the following weeks, whereas late effusions and constriction may emerge after much longer intervals. A cancer history dating back decades may therefore remain relevant. Conversely, a short interval does not justify overlooking other acute causes, particularly in patients receiving chemotherapy, immunotherapy, or invasive procedures at the same time.

Modern techniques for dose conformality and respiratory motion control have reduced exposure compared with many historical protocols. The benefit, however, depends on the individual plan, target geometry, and the compromises required for tumor control. Percentages derived from older cohorts treated with large mediastinal fields do not automatically describe contemporary risk. Likewise, the lower frequency of acute forms does not eliminate the need to monitor late effects.

Associated therapies may modify overall cardiac injury. Anthracyclines, other cytotoxic agents, and immunologic treatments introduce distinct, sometimes overlapping mechanisms; myocardial dysfunction may promote effusion even without active radiation pericarditis. Age, pre-existing cardiovascular disease, renal function, and vascular risk factors influence functional reserve and prognosis. Not all of these elements are specific predictors of pericardial injury, but they are necessary for interpreting its clinical consequences.

Cohort studies after lung chemoradiotherapy show associations between cardiac dose distribution and the development of effusion. These observations support attention to treatment planning but do not identify a universal rule valid for every tumor, technique, or patient. The frequency of small radiologic effusions differs from that of symptomatic pericarditis, tamponade, or constriction. Separating these outcomes avoids overestimating clinically relevant disease or, conversely, ignoring a finding that warrants monitoring.

Tissue injury and pathophysiologic consequences

Microvascular injury is a central step in radiation damage. Endothelial alterations, increased permeability, and the inflammatory response promote exudation into the pericardial sac. The initial injury may be followed by incomplete repair, reduction of the capillary network, and extracellular matrix deposition. These processes do not necessarily progress at the same rate in all irradiated regions, producing a picture in which inflammatory activity and scarring may coexist rather than represent completely separate phases.

Impaired lymphatic drainage contributes to fluid accumulation together with changes in permeability. An effusion may therefore persist when fever, pain, and inflammatory markers are absent. This distinction has therapeutic consequences: reducing inflammation does not necessarily restore an impaired reabsorption system. The presence of fluid on echocardiography is not sufficient to conclude that anti-inflammatory treatment should be intensified, particularly in a patient exposed to renal, bleeding, or infectious risks.

Pericardial fibrosis may thicken and fuse the pericardial layers, sometimes with calcification. The anatomic finding, however, does not always correspond to functional limitation: some thickened pericardia remain hemodynamically tolerated, whereas constriction may be present without marked thickening. Clinical significance derives from the ability of the sac to accommodate filling and from transmission of respiratory pressure changes, not from wall appearance on imaging alone.

In constriction total cardiac volume is constrained and the ventricles compete more strongly for the available space. Respiratory changes accentuate ventricular interdependence, promoting venous congestion and reducing the ability to increase cardiac output during exercise. Radiation injury to the myocardium may add an intrinsic restrictive component. The combination of the two mechanisms is particularly important because removal of the pericardium does not correct myocardial stiffness.

Tamponade instead results from rising fluid pressure until filling is impaired. The rate of accumulation, residual distensibility, and volume status modify the relationship between volume and circulatory compromise. Adhesions and loculated collections may selectively compress one chamber and make classic signs less evident. Effusive-constrictive physiology combines a pressure component from fluid with a constraint that persists after drainage.

Associated cardiac disease may involve the coronary arteries, valves, conduction system, and myocardium. Dyspnea and congestion may therefore have multiple determinants even when the pericardium is clearly abnormal. Significant valvular regurgitation, ischemia, or ventricular dysfunction modifies the expected benefit of pericardial procedures. Pathophysiology must be reconstructed as the sum of potentially interacting lesions: identifying one plausible cause does not end the investigation of other correctable components.

Clinical presentation, history, and physical examination

The early inflammatory form may present with pleuritic or positional chest pain, low-grade fever, and a friction rub. Pain tends to worsen with inspiration and the supine position, but the presentation may be incomplete. Esophagitis, pneumonitis, chest wall pain, ischemia, and pulmonary embolism may produce overlapping symptoms during cancer treatment. The relationship with the radiotherapy schedule guides suspicion, but clinical assessment must first distinguish conditions requiring urgent intervention.

Late effusion may be incidental or cause progressive dyspnea, fatigue, orthopnea, and reduced exercise tolerance. The absence of pain and fever is compatible with a predominantly fibrotic or lymphatic mechanism. A collection detected on oncologic CT requires echocardiographic correlation when its size, symptoms, or course make this necessary. The radiologic report documents anatomy but does not by itself establish how much the fluid interferes with filling under the patient's physiologic conditions.

The constrictive presentation includes dependent edema, ascites, abdominal fullness, hepatomegaly, and jugular venous congestion. Dyspnea may occur with preserved ejection fraction and be mistakenly attributed only to lung disease or deconditioning. Kussmaul sign and a pericardial knock may support suspicion but are not mandatory. Ascites resistant to usual treatments warrants cardiac assessment when there is a history of mediastinal irradiation.

The radiotherapy history should reconstruct the site, year, prescribed dose, fractionation, and techniques used, retrieving the treatment plan when available. Previous courses involving the same region and thoracic procedures should be recorded together with systemic therapies. Comparison with earlier echocardiograms and CT scans helps establish whether thickening or fluid was already present. This chronology is more informative than a generic note of previous radiotherapy and helps discussion with the radiation oncologist.

The physical examination includes blood pressure, heart rate, peripheral perfusion, venous pressure, respiratory findings, and signs of congestion. Pulsus paradoxus, hypotension, oliguria, or altered mental status indicate possible advanced compromise, but preserved blood pressure does not exclude compensated tamponade. Comorbidities may mask findings: pulmonary fibrosis and pleural effusion accentuate dyspnea, whereas neuropathy or analgesics alter pain perception. Change from the usual functional level should be given appropriate weight.

Current oncologic risk must be assessed independently of the time elapsed since radiation. Weight loss, lymphadenopathy, a new mass, radiologic progression, or a rapidly recurrent effusion require consideration of a malignant cause. Even in a patient in remission, infections and new neoplasms may modify the picture. Attribution to radiotherapy is stronger when exposure, phenotype, and investigations are concordant, not simply when a long time has passed without specialist follow-up.

Investigations and differential diagnosis

Echocardiography is the initial test to quantify and localize the effusion, look for chamber collapse, and assess respiratory flow changes. It should include biventricular function, valves, and estimated pulmonary pressure. A small collection does not exclude pericarditis, whereas a large collection without compressive signs requires clinical assessment distinct from tamponade. When acoustic windows are difficult or collections are posterior, additional imaging may clarify the relationship between fluid and cardiac chambers.

The electrocardiogram may show diffuse repolarization and PR-segment changes in acute forms, but it may be normal or altered by concomitant conditions. Complete blood count, C-reactive protein, renal function, and troponin help identify inflammation, medication-related risk, and possible myocardial injury. No biomarker proves a radiation origin. Elevated troponin requires interpretation in relation to ischemia, myocarditis, and other causes; it should not automatically be incorporated into a diagnosis of isolated pericarditis.

Computed tomography defines calcification, thickening, loculations, and relationships with the mediastinum and lungs. It also allows assessment for tumor progression and planning of procedures. Smooth or calcific thickening may be compatible with chronic injury but is not pathognomonic. Nodules and masses increase suspicion of neoplasia without identifying the histologic type by themselves. The usefulness of contrast must be balanced against renal function and the clinical question, avoiding repeated examinations that do not change management.

Cardiac magnetic resonance assesses edema, pericardial enhancement, septal motion, and myocardial involvement. Documented inflammatory activity may support a therapeutic trial in stable potentially reversible cases. Enhancement must be interpreted with symptoms, markers, and course because it may persist during remodeling. Magnetic resonance does not replace stabilization of a patient with tamponade and does not automatically turn a tissue finding into proof of radiation causality.

The diagnosis of constriction integrates respiratory septal shift, flow Doppler, tissue velocities, and hepatic vein behavior. Associated myocardial injury may attenuate some findings normally used to distinguish constriction from restriction. In discordant cases, catheterization with simultaneous respiratory assessment of ventricular pressures may clarify physiology. Equalization of diastolic pressures alone is not specific: it must be interpreted together with ventricular dynamics and morphologic information.

Etiologic confirmation primarily requires reasoned exclusion of alternatives. If fluid is drained, cytology and microbiology are selected according to context; a negative sample does not exclude every neoplasm or infection. Targeted biopsy may be useful in the presence of suspicious lesions or during surgery, whereas it is not necessary in every typical stable presentation. Histologic fibrosis and inflammation are compatible with irradiation but do not constitute a unique signature of radiation injury.

Definition of disease and assessment before treatment

Functional classification should specify whether painful inflammation, effusion without inflammation, tamponade, constriction, or a combination predominates. This formulation is more useful than an etiologic label alone because it determines immediate interventions and follow-up goals. The course of the fluid, biologic activity, exercise limitation, and signs of organ injury should be reported. A stable patient with recent inflammation raises different questions from a person with chronic ascites and diffuse calcification.

Reversibility is assessed by integrating symptom duration, biomarkers, tissue imaging, and response to appropriate treatment. A constrictive presentation with inflammatory activity may have a transient component; a long history of congestion, extensive fibrosis, and little activity makes complete regression less likely. No single finding, however, decides the issue by itself. Therapeutic observation is reasonable only when hemodynamic conditions allow it and delay does not expose the patient to progressive deterioration.

Coronary assessment is particularly important in irradiated survivors, especially in the presence of symptoms, risk factors, or planned surgery. The choice between anatomic and functional methods depends on clinical probability and the planned intervention. Likewise, valvular disease and ventricular dysfunction must be quantified. Identifying an associated lesion may modify both the surgical strategy and the expected recovery after pericardiectomy, avoiding attribution of a multifactorial limitation to the pericardium alone.

Extracardiac reserve includes pulmonary function, nutritional status, liver, and kidneys. Previous thoracotomies, mediastinal fibrosis, and radiotherapy may make surgical access more complex; advanced congestion and cachexia further increase vulnerability. Risk should not be inferred solely from generic scores, which may incompletely represent these elements. Multidisciplinary assessment helps distinguish risks that can be corrected before intervention from structural limitations that reduce its benefit.

The oncologic situation guides timing and proportionality of care. In a patient with long life expectancy, definitive treatment of constriction may have substantial value; in rapidly progressive cancer, symptomatic drainage may better meet treatment goals. This decision does not follow simply from the presence of cancer but from treatability, symptoms, independence, and preferences. Even a palliative intervention requires accurate physiologic diagnosis of the problem to be relieved.

The follow-up plan should be defined before a conservative strategy is started. It includes clinical parameters, biomarkers when informative, echocardiography, and criteria for earlier reassessment. Lack of radiologic change does not guarantee functional stability, just as a small residual effusion does not imply treatment failure. The goal is to document improvement in symptoms and circulation, distinguishing it from persistence of scar findings that may remain visible for years without requiring further treatment.

Treatment of inflammation, effusion, and constriction

Anti-inflammatory therapy is indicated when active pericarditis is present. Aspirin or an NSAID, generally combined with colchicine when appropriate, follows the principles used for other acute forms, with dose and duration adapted to renal function, bleeding risk, and interactions. Evidence specific to radiation-induced disease is limited: use derives mainly from management of the pericardial syndrome. An isolated effusion without inflammatory activity does not automatically justify the same treatment or indefinite prolongation.

Colchicine requires attention to renal or hepatic impairment, cytopenias, and drugs that increase its exposure. Cancer therapy may introduce clinically relevant interactions and should be reviewed as a whole. Corticosteroids are reserved for selected indications, contraindication to or inadequate response to initial approaches, after infections and other causes have been considered. They cannot erase established radiation fibrosis; symptomatic improvement does not prove that the entire hemodynamic limitation is reversible.

Drainage is urgent in clinically significant tamponade and may be needed for persistent symptomatic collections or for a diagnostic question. Image-guided pericardiocentesis and surgical drainage are selected according to distribution, accessibility, adhesions, and overall condition. A catheter kept in place until output falls may limit reaccumulation in appropriate settings. The material should be analyzed when the cause is not sufficiently defined, because attributing the effusion to radiation does not make the search for malignancy unnecessary.

A pericardial window may be useful for recurrences or when percutaneous access is inadequate, but it does not correct diffuse constriction. After decompression, venous pressure, symptoms, and Doppler physiology should be reassessed: persistent congestion may indicate residual constraint, myocardial disease, or valvular disease. The choice of procedure should anticipate these possibilities. Repeating drainage without demonstrating new compression may expose the patient to risk without addressing the dominant mechanism.

Pericardiectomy is the definitive treatment for symptomatic irreversible chronic constriction in selected patients. After radiotherapy it may be technically difficult and provide less benefit than in idiopathic forms, particularly because of concomitant cardiac and mediastinal injury. Assessment in experienced centers is indicated, with attention to the extent of resection, associated lesions, and the possibility of recovery. Diuretics relieve congestion but do not remove the constraint and require caution to avoid excessive reduction in preload.

Continuity of oncologic care requires discussion among the cardiologist, oncologist, and radiation oncologist when the event occurs during treatment. Severity, the possibility of modifying the plan, and the risk of interruption guide the decision; a single rule for treatment interruption is not appropriate. There is insufficient basis for routinely prescribing colchicine or biologic drugs to prevent radiation fibrosis. In rare refractory inflammatory recurrences, any advanced therapy requires phenotype confirmation and specialist assessment distinct from management of scarring.

Prognosis, complications, and long-term surveillance

Pericardial prognosis ranges from complete recovery after an inflammatory episode to persistent effusion or constriction. It does not coincide with oncologic prognosis or with that of radiation-induced heart disease as a whole. A small stable collection may have little immediate relevance, whereas constriction with hepatic congestion or renal failure may markedly limit independence and survival. Estimates should refer to the actual phenotype and other lesions rather than using a single percentage for all presentations.

Hemodynamic complications include tamponade, reduced cardiac output, systemic congestion, and effusive-constrictive physiology. Recurrent fluid may require additional procedures, whereas unrecognized constriction may lead to malnutrition and hepatorenal deterioration. The possibility of recovery decreases as organ injury becomes advanced. Surgical assessment therefore should not be delayed until reserve is completely lost in patients with a potentially correctable lesion.

Surgical series have shown less favorable outcomes for post-radiation constriction than for some other etiologies. This association does not mean that every irradiated patient is inoperable: it also reflects comorbidity, myocardial injury, valvular disease, and mediastinal complexity. Individual decisions must be based on a contemporary balance of benefits and risks. Presenting a historical median as an individual's destiny may discourage useful care or create incorrect expectations about how much pericardial resection can correct.

Survivor surveillance should continue beyond resolution of the episode. Radiotherapy history, available cardiac dose, associated treatments, and risk profile determine the intensity and frequency of cardio-oncology follow-up. New symptoms require assessment earlier than any scheduled interval. Surveillance is not limited to fluid: it includes ventricular and valvular function and, when indicated, coronary disease. A previously normal echocardiogram does not eliminate the risk of late manifestations.

Primary prevention is based on reducing cardiac exposure to the extent compatible with oncologic efficacy. Personalized planning, respiratory techniques, and selection of radiotherapy modality should be discussed by the appropriate team. Blood pressure control, smoking cessation, and metabolic management reduce overall cardiovascular risk, although they are not specific treatments for pericardial fibrosis. The patient should retain a summary of treatments received, useful when symptoms emerge many years later in a different care setting.

Quality of life and the ability to perform daily activities are outcomes to monitor together with imaging. Return to exercise after inflammation should be graded according to remission and myocardial involvement, whereas rehabilitation in chronic forms must take the entire heart disease into account. Increasing dyspnea, syncope, rapidly developing edema, or reduced urine output require prompt reassessment. Effective management combines recognition of emergencies, treatment of the predominant mechanism, and prolonged observation for possible associated lesions.

References
1. Schulz-Menger J et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. European Heart Journal. 2025;46(40):3952-4041.
2. Klein AL et al. Pericardial Diseases: International Position Statement on New Concepts and Advances in Multimodality Cardiac Imaging. JACC: Cardiovascular Imaging. 2024;17(8):937-988.
3. Adler Y et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2015;36(42):2921-2964.
4. Mitchell JD et al. Cardiovascular Manifestations From Therapeutic Radiation: A Multidisciplinary Expert Consensus Statement From the International Cardio-Oncology Society. JACC: CardioOncology. 2021;3(3):360-380.
5. Lancellotti P et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. European Heart Journal - Cardiovascular Imaging. 2013;14(8):721-740.
6. Ning MS et al. Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics. 2017;99(1):70-79.
7. Lyon AR et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal. 2022;43(41):4229-4361.
8. Mori S et al. Pericardial effusion in oncological patients: current knowledge and principles of management. Cardio-Oncology. 2024;10:8.
9. Roberts WC. Pericardial heart disease: its morphologic features and its causes. Proceedings (Baylor University Medical Center). 2005;18(1):38-55.
10. Spodick DH. Acute cardiac tamponade. New England Journal of Medicine. 2003;349(7):684-690.
11. Welch TD et al. Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria. Circulation: Cardiovascular Imaging. 2014;7(3):526-534.
12. Sagristà-Sauleda J et al. Effusive-constrictive pericarditis. New England Journal of Medicine. 2004;350(5):469-475.
13. Bertog SC et al. Constrictive pericarditis: etiology and cause-specific survival after pericardiectomy. Journal of the American College of Cardiology. 2004;43(8):1445-1452.
14. Imazio M et al. A randomized trial of colchicine for acute pericarditis. New England Journal of Medicine. 2013;369(16):1522-1528.
15. U.S. National Library of Medicine. COLCHICINE tablet, film coated: prescribing information. DailyMed. n.d. Accessed September 26, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50b9c910-49a3-4a57-80f5-dc36c09da4df.